Practically every organization in every sector of healthcare routinely needs market-sizing models to guide high-stakes strategic decisions, such as where to invest and where to be cautious. The problem: In the rush to check all the planning boxes, it is all too easy for leaders to accidentally end up with—and even bet the strategy on—'models' that are not really models at all, but simply numbers . Numbers with unexamined, opaque, and sometimes wildly inaccurate underlying as

January 2026 has slipped away like a Nor'easter through the Northeast—fast, furious, and leaving everyone wondering what just happened. And much like those of you who got snowed in, we've spent the month mostly indoors, heads down, reading everything we could get our hands on about the flurry of health industry and policy developments that have swept through Washington and across the healthcare landscape. Let's go around the horn and touch on just a sliver of what our team h

Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s). Originally developed for diabetes management, these drugs, popularized under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, are redefining how we think about obesity, metabolic health, and even chronic disease prevention. And increasingly, GLP-1s are no longer just about controlling blood sugar. They have become c

MAHA's recent strategic plan announced its intent to create a comprehensive real-world data asset to fuel research. However, any desire to move from data source to insight is likely to be more complex than merely acquiring some data. What potential pitfalls could lie ahead and what can other organizations learn from this?

Today's post is the third in an ongoing series we're publishing on key players in healthcare vertical integration . Nearly everyone in...

Last year at this time, we enjoyed reading Dan Diamond's piece for the Washington Post on how reversing the recent decline in U.S....

In last week's blog post, we delved into the what and why behind the current surge in interest and demand for GLP-1s. And it's clear that...

A full 6% of US adults are taking GLP-1s. In this post, we break down what we do—and don't—know about these medications as of August 2024.

Healthcare disruption has been a hot (and noisy) topic in recent years. For the last decade, the healthcare industry has been rich in...

Everybody likes to pick on the PBMs (pharmacy benefit managers) these days. It's a sector of healthcare whose business model...

Something we're starting new this week: Union Healthcare Insight's Slide of the Week. Over the past 12 months we've been in business, our...

This month, my family and I were affected by two different drug shortages. First, we couldn’t fill a standing prescription for an ADHD...